Healthcare Global Enterprises Ltd. · NSE:HCG
Healthcare Global Enterprises — Q3 FY2026 Earnings Presentation
22 slides from Healthcare Global Enterprises's earnings presentation, Feb 6, 2026
Slide 1: Exchange cover letter: Investor Presentation (Updated)
February 06, 2026 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Dear Sir/Madam,
Slide 2: Q3 & 9MFY26 Results Presentation
HEALTHCARE GLOBAL ENTERPRISES LIMITED Q 3 & 9MF Y2 6 R e s u l ts P r e s e n tat io n February 5, 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This p
Slide 4: Largest Pan-India Oncology Focused Hospital Chain
Largest Pan -India Oncology Focused Hospital Chain Our Presence 19 / 10 25 38 Cities / States 1 Hospitals 2 No. of LINACs3 Jaipur 98 2.5k+ Operation Theatres 2 Capacity Beds 2 Ahmedabad Indore Ranchi Kolkata Rajkot Baroda Bhavnagar Nagpur Cuttack Nashik 9MFY26 Operational and Financial Metrics Vizag
Slide 5: HCG Key Highlights: Q3FY26
HCG Key Highlights: Q3FY26 HCG delivered revenue of INR 6,331mn in Q3 FY26 vs INR 5,586mn in Q3FY25, reflecting a growth of ~13% YoY; Excluding Milann, HCG delivered YoY revenue growth of ~13% driven by ~8% growth in volumes and ~5% growth in ARPP • Broad based growth continued in Q3 across the 3 ke
Slide 6: Financial Highlights: Q3FY26
Financial Highlights: Q3FY26 Overall Revenue Adjusted Overall EBITDA1 Adjusted PAT (Post - IND AS)2 Margin (%) 16.5% 17.5% Q3FY26 PAT (post Non controlling +13% +20% interest) lower on account of higher depreciation and interest expense 6,331 70 from growth investments / 1,108 acquisitions and posit
Slide 7: Financial Highlights: 9MFY26
Financial Highlights: 9MFY26 Overall Revenue Adjusted EBITDA1 Adjusted PAT (Post - IND AS) 2 ROCE3 Margin (%) 17.7% 18.3% +16% +20% 18,931 3,458 16,377 13% 13% 2,893 371 216 9MFY25 9MFY26 9MFY25 9MFY26 9MFY25 9MFY26 9MFY25 9MFY26 Revenue (excl. Fertility) Volumes4 (excl. Fertility) ARPP (excl. Ferti
Slide 8: 9MFY26 Revenue Mix: By Specialty and Payor
9MFY26 Revenue Mix: By Specialty and Payor Non Oncology Others 10% 10% OP Onco Medical services Oncology 17% 38% Specialty Payor Government Mix 33% Mix Cash + TPA 55% Surgical Oncology 20% Radiation International Oncology 2% 15% (1) OP services includes OPD consultation, diagnostics and pharmacy. (2
Slide 9: Region-wise Performance Update: South
Region-wise Performance Update: South (# of IP patients) + 16% Revenue Share % 92,821 + 1% 80,081 9M 39% Overall Vizag Gulburga FY26 29,693 30,114 Vijaywada Volumes Hubli Ongole Shimonga Bed share % Q3FY25 Q3FY26 9MFY25 9MFY26 Bangalore Chennai + 7% -1% 9M 40% FY26 76,080 81,666 79,709 79,110 Overal
Slide 10: Region-wise Performance Update: West
Region-wise Performance Update: West (# of IP patients) + 9% Revenue Share % + 11% 83,021 90,187 45% 9M Overall Jaipur FY26 30,289 27,386 Volumes Indore Rajkot Ahmedabad Baroda Nagpur Bed share % Q3FY25 Q3FY26 9MFY25 9MFY26 Bhavnagar Nashik 47% Mumbai + 5% + 6% 9M FY26 93,827 93,862 89,067 88,688 Ov
Slide 11: Region-wise Performance Update: East
Region-wise Performance Update: East (# of IP patients) + 11% Revenue Share % 11% + 16% 29,437 32,647 9M Overall FY26 11,326 Volumes 9,792 Ranchi 89% Kolkata Bed share % Q3FY25 Q3FY26 9MFY25 9MFY26 Cuttack 13% 9M - 3% + 1% FY26 65,509 63,693 64,598 65,256 Overall ARPP Q3FY26 Highlights: Q3FY25 Q3FY2
Slide 12: Region-wise Performance Update: International and Milann
Region-wise Performance Update: International and Milann Revenue Share % Revenue (INR Mn) 5% + 86% 544 9M Kenya FY26 International + 42% 292 Nairobi (Kenya) Milann 157 111 Q3FY25 Q3FY26 9MFY25 9MFY26 + 2.5% Q3 FY26 Highlights: 437 448 • Kenya Operations − Revenue growth of 42% YoY, driven by strong
Slide 13: Capital Expenditure & Net Debt
Capital Expenditure & Net Debt Capital Expenditure (INR Mn) Net Debt (INR Mn) Regions 9MFY25 9MFY26 Net Debt Items 31 st Dec 2025 30 th Sep 2025 South 966 1,433 Bank Debt (1) 8,617 8,549 Vendor Finance (2) 191 187 West 663 637 Other Debt 114 114 East 109 104 Less: Cash & Cash Equivalents (3) (1,193)
Slide 14: Q3 & 9MFY26 Consolidated Profit & Loss Account
Q3 & 9MFY26 Consolidated Profit & Loss Account Profit and Loss (INR in Mn.) Q3FY25 Q3FY26 Y-o-Y 9MFY25 9MFY26 Y-o-Y Revenues from Operations 5,576 6,312 16,347 18,881 Income from Govt. Grant 10 19 30 49 Total Revenue from Operations 5,586 6,331 13% 16,377 18,931 16% Cost of Goods Sold (1,491) (1,766
Slide 15: HCG: India's Leading Oncology Platform
HCG: India’s Leading Oncology Platform 14 www.hcgoncology.com www. h c g o n c o l o g y. c o m
Slide 16: A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment
A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment Largest oncology-focused hospital chain Best-in-class medical talent pool with with a pan-India network industry-leading retention Deepest network across metros and Focused approach and non-metros; leading¹ positions in Tumor
Slide 17: Proven Track Record of Successfully Delivering Profitable Growth Consistently
Proven Track Record of Successfully Delivering Profitable Growth Consistently Revenue INR Mn Expansion Phase Consolidation Phase CAGR ~15% 22,228 19,121 CAGR 16% 16,948 13,978 CAGR 27% 10,956 10,134 5,194 1,600 FY10 FY15 FY20 FY21 FY22 FY23 FY24 FY25 Adjusted EBITDA1 INR Mn Expansion Phase Consolida
Slide 18: HCG is Positioned as the 'Destination for Cancer Care'
HCG is Positioned as the ‘Destination for Cancer Care’ with Superior Clinical and Non -clinical Expertise… Diagnostics Treatment Post Care Genomics and Digital PET Preventive Medical Oncology Radiation Oncology Surgical Molecular Imaging Psychological Preventive Molecular Oncology and Haemato- Oncol
Slide 19: …including Cutting-edge Technology
…including Cutting -edge Technology TRACK RECORD OF BEING 1st TO LAUNCH State-of-the-art Equipment in each modality ADVANCED TECHNOLOGY IN INDIA DIAGNOSTICS Total PET CTs : 19 2026 MR-LINAC1 AI- based 2022 Digital PET Digital CT Automated Digital Skyra Tesla 3T Molecular / RIS PACS Pathology Breast
Slide 20: Strategic Priorities
Strategic Priorities Clinical Outcomes, Growth and Profitability A B C D Optimize Existing Improve Network Enhance Patient Invest in Growth Network Efficiency Experience 1. Build best-in-class talent → 1. Brownfield expansion across 1. Undertake prudent cost 1. Invest in upgrading existing improve c
Slide 21: About Us: HealthCare Global Enterprises Ltd.
CIN: L15200KA1998PLC023489 About Us: HealthCare Global Enterprises Ltd. For updates and specific queries, please visit www.hcgoncology.com or contact: (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 22 comprehensive cancer centers across Hea
Slide 22: THANK YOU
THANK YOU www.hcgoncology.com www. h c g o n c o l o g y. c o m
HealthCare Global Enterprises — Q3 FY2026 Earnings Presentation on 6ix